Developer · NMRA · United States
Neumora Therapeutics, Inc.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapies for brain diseases, including neuropsychiatric and neurodegenerative disorders. Its pipeline has centered on the kappa-opioid receptor antagonist navacaprant (discontinued in 2026 after Phase 3 failures in major depressive disorder) and the vasopressin V1a antagonist NMRA-511 for Alzheimer's disease agitation.
Pipeline (2)
- Agitation in Alzheimer's diseasePhase 1Active
- Major depressive disorderDiscontinuedDiscontinued
Deals & partnerships
- Navacaprant (NMRA-140)Licensor BlackThorn Therapeutics, Inc.
- NMRA-511Licensor BlackThorn Therapeutics, Inc.
- Oct 7, 2021AcquisitionNeumora acquires BlackThorn Therapeutics, gaining navacaprant (NMRA-140) and NMRA-511Neumora Therapeutics acquired BlackThorn Therapeutics, Inc. (completed October 7, 2021; BlackThorn became a wholly owned subsidiary, later dissolved). The acquisition brought in BlackThorn's CNS programs, including the kappa-opioid receptor antagonist navacaprant (NMRA-140 / BTRX-335140) and the vasopressin V1a antagonist NMRA-511 (BTRX-323511), both originally licensed by BlackThorn from The Scripps Research Institute (TSRI) under a 2015 worldwide exclusive license.
Catalysts · 2 upcoming · 3 reported
- 2H 2026Anticipated
NMRA-511forAgitation in Alzheimer's diseaseInterim analysis
Anticipated readout from a multiple ascending dose (MAD) expansion cohort evaluating higher doses of NMRA-511, expected in 2H 2026.
- Q1 2027Anticipated
NMRA-511forAgitation in Alzheimer's diseaseRegistry results
Anticipated initiation of a Phase 2 study of NMRA-511 in Alzheimer's disease agitation, planned for Q1 2027.
Recently reported
- 2026-06-15missed
Navacaprant (NMRA-140)forMajor depressive disorderTopline data
KOASTAL-2 and KOASTAL-3 both missed; Neumora discontinued navacaprant for MDD.
- 2026-01-05met
NMRA-511forAgitation in Alzheimer's diseaseTopline data
NMRA-511 Phase 1b signal-seeking study in Alzheimer's disease agitation met its goal: clinically meaningful placebo-adjusted CMAI reductions (notably 7.6/5.6 points at weeks 6/8 in the elevated-anxiety subgroup), favorable safety, no somnolence/sedation.
- 2025-01-02missed
Navacaprant (NMRA-140)forMajor depressive disorderTopline data
KOASTAL-1 missed primary (MADRS) and key secondary (SHAPS) endpoints at Week 6.
Recent activity
- Jun 15, 2026ReadoutNavacaprant (NMRA-140)·Major depressive disordermissedKOASTAL-2 and KOASTAL-3 both missed; Neumora discontinued navacaprant for MDD.source ↗
- Jan 5, 2026ReadoutNMRA-511·Agitation in Alzheimer's diseasemetNMRA-511 Phase 1b signal-seeking study in Alzheimer's disease agitation met its goal: clinically meaningful placebo-adjusted CMAI reductions (notably 7.6/5.6 points at weeks 6/8 in the elevated-anxiety subgroup), favorable safety, no somnolence/sedation.source ↗
- Nov 19, 2025Phase changeNMRA-511·Agitation in Alzheimer's diseasePhase 1Phase 1b study NCT06546995 reached primary completion (per ClinicalTrials.gov), with overall status COMPLETED.source ↗
- Jan 2, 2025ReadoutNavacaprant (NMRA-140)·Major depressive disordermissedKOASTAL-1 missed primary (MADRS) and key secondary (SHAPS) endpoints at Week 6.source ↗
- Jul 9, 2024Phase changeNMRA-511·Agitation in Alzheimer's diseasePhase 1Phase 1b signal-seeking study (NCT06546995) initiated; two-part design (Part A: ~8 healthy elderly safety/PK; Part B: AD agitation efficacy at NMRA-511 20 mg BID). A prior Phase 1a in 92 healthy adults (doses 5-40 mg, well tolerated, no SAEs) preceded it; no NCT located for the Phase 1a.source ↗
- Jul 18, 2023Phase changeNavacaprant (NMRA-140)·Major depressive disorderPhase 3KOASTAL Phase 3 program initiated after End-of-Phase 2 FDA meeting.source ↗
- Apr 8, 2022Phase changeNavacaprant (NMRA-140)·Major depressive disorderPhase 2Phase 2a proof-of-concept (NCT04221230, n=204) completed; primary HAMD-17 endpoint not met in the overall efficacy population (included mild MDD), but significant improvement in the moderate-to-severe subgroup.source ↗
Competitive landscape
Other companies developing against Neumora Therapeutics, Inc.'s targets or indications.
- Axsome Therapeutics, Inc.2 compoundsMajor depressive disorderAgitation in Alzheimer's disease
- Cerevel Therapeutics Holdings, Inc.1 compoundKORMajor depressive disorder
- Intra-Cellular Therapies, Inc.2 compoundsMajor depressive disorderAgitation in Alzheimer's disease
- Johnson & Johnson2 compoundsKORMajor depressive disorder
- Alto Neuroscience, Inc.2 compoundsMajor depressive disorder
- Autobahn Therapeutics, Inc.1 compoundMajor depressive disorder
- Beckley Psytech Limited1 compoundMajor depressive disorder
- Biohaven Ltd.1 compoundMajor depressive disorder
- BioXcel Therapeutics, Inc.1 compoundAgitation in Alzheimer's disease
- Boehringer Ingelheim International GmbH2 compoundsMajor depressive disorder
- COMPASS Pathways plc1 compoundMajor depressive disorder
- CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.1 compoundMajor depressive disorder
